20 May 2026

Oncoinvent ASA: Grant of share options to member of the Board following AGM

Oslo, Norway, 20 May 2026: Reference is made to the Annual General Meeting (the “AGM”) of Oncoinvent ASA (the “Company”) earlier today where the nomination committee's proposal for remuneration for the members of the Board was approved.

The AGM approved the following share option remuneration to the Board.

  • Chair of the Board: 1,708 share options
  • Board members: 854 share options

Share options normally vest over a four-year period as follows: no options shall vest during the first 12 months following the date of the grant, 13/48 of the options shall vest in the 13th month, the remaining options shall thereafter vest in equal monthly instalments of 1/48. Options expire seven years after the grant date.

The exercise price for this grant is NOK 46,5195 per option equal to the volume weighted average share price (VWAP) the last day before the grant.  

The following members of the Board of Oncoinvent ASA has received share options grants, according to the terms described above:

  • Gillies O’Bryan-Tear (Chairperson of the Board) has been granted 1,708 share options. Following the grant, he holds 26,369 shares and 5,245 share options in Oncoinvent ASA.
  • Kari Grønås (Board member) has been granted 854 share options. Following the grant, she holds 902 shares and 2,506 share options in Oncoinvent ASA.
  • Hilde Steineger (Board member) has been granted 854 share options. Following the grant, she holds no shares and 2,506 share options in Oncoinvent ASA.
  • Orlando Oliveira (Board member) has been granted 854 share options. Following the grant, he holds no shares and 2,506 share options in Oncoinvent ASA.
  • Johan Häggblad (Board member) has been granted 854 share options. Following the grant, he holds no shares and 1,804 share options in Oncoinvent ASA.
  • Olav Hellebø (Board member) has been granted 854 share options. In addition, he receives an option grant equivalent to the option allocation to Board members of Oncoinvent ASA approved by the 2025 AGM, adjusted for actual time served, amounting to a total of 554 share options. These options are granted at an exercise price equal to the volume weighted average share price (VWAP) on the last trading day before the merger; both the number of share options and exercise price have been adjusted for the previous reverse share split and reduction of nominal value. Following these grants, he holds 2,000 shares and 1,408 share options in Oncoinvent ASA.

PDMR notifications 20 May 2026 – grant of board options.pdf

This information is subject to the disclosure requirements pursuant to article 19 of the regulation EU 596/2014 (the EU Market Abuse Regulation) and section 5-12 of the Norwegian Securities Trading Act.

PDMR notifications 20 May 2026 - grant of board options

For further information, please contact:

Oystein Soug, Chief Executive Officer
Email: IR@oncoinvent.com



About Oncoinvent

Oncoinvent is developing Radspherin®, a receptor-independent alpha radiation therapy that leverages the unique anatomy of the abdominal cavity to destroy residual micrometastases using a single, highly localized dose of alpha radiation. The initial clinical focus is treatment of ovarian and colorectal cancer patients after surgical removal of the primary tumor and visible metastases in the peritoneum, the thin membrane lining the abdominal cavity and covering the abdominal organs.

This radiopharmaceutical is designed to prevent or delay recurrence in the peritoneal cavity, keeping patients disease-free for longer than the current standard of care and thereby also impacting overall survival. It is broadly applicable to any cancer that spreads to the peritoneum, e.g. ovarian, colorectal, and gastric cancers. Radspherin® stands out for its simplicity, excellent safety profile, and seamless integration into existing surgical workflows. Oncoinvent’s product is easy to use, avoids systemic delivery and significant toxicity. It is also differentiated in being simple to manufacture, scalable, and supply de-risked.

Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers, are highly promising, showing an excellent safety profile and meaningful signals of efficacy. Interim data from an ongoing, randomized, controlled phase 2 ovarian cancer trial is expected in 2026. With cost-effective manufacturing, blockbuster potential, active pharma partnership momentum, plus strong endorsements from leading experts, Oncoinvent is built for scale and commercial success, and is set to become the new standard for post-surgical cancer care. The Company was founded by the originators of Algeta and Xofigo (acquired by Bayer).

Øystein Soug

Chief Executive Officer

soug@oncoinvent.com

Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.

Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997

close

Anders Månsson

Chief Executive Officer

mansson@oncoinvent.com

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.

close